Adult subjects ( percentage of predicted forced expiratory volume in 1s ( FEV1 ) 60-85 % ) were randomized to OC000459 at three dose levels ( 25mg once daily , 200mg once daily or 100mg twice daily ) or placebo for 12weeks ( n = 117-125 per group , full analysis set ) .